BioLife Solutions, Inc. (BLFS)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$35.25-0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
BioLife grows revenue 25% yearly, hitting $113.75M in 2026. Profit margin stays near 64%. Net income rose to $1.2M in Q1 2026. The company is improving profits and sales steadily.
Margins fell from 67% to 64%. The company still loses money overall. Growth may slow below analyst expectations.
The market expects about 21% revenue growth. Our fair value is $18.13, slightly above the current price. We see risk if growth or margins weaken.
Breaks if: Gross margin falls below 60% in FY26
Breaks if: Net income falls below $0.5 million quarterly
Breaks if: Revenue falls below $93 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a growth-oriented thesis focused on a company that is currently loss-making but has shown strong revenue growth and improved net income. The thesis is intact, supported by recent positive earnings and acquisition news, but is tempered by valuation concerns.
The market currently prices BLFS at an expensive valuation compared to its peers, reflecting high expectations for future growth. There is a notable expectations gap, indicating that the market may be anticipating continued strong performance without fully accounting for potential risks.
Management is focused on increasing revenue growth, which has been strong recently, but gross margin expansion has been limited. The company has shown significant improvement in net income, although it remains a loss-making entity overall, indicating mixed results in fundamental performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Continue to grow revenue through expanding market share in cell and gene therapy products and clinical trials.
Stated as a priority in 4 quarters including 2026-Q2 and 2026-Q1. Revenue grew from $22.1 million in 2025-Q1 to $27.5 million in 2026-Q1 (+25%), and from $23.4 million in 2025-Q2 to $28.5 million in 2026-Q2 (+21%). Management has raised 2025 revenue guidance multiple times, reflecting growth momentum. The trajectory is delivering consistent revenue growth aligned with management's stated priority.
“Total revenue of $28.5 million, up 21% over Q2 2025”
“Total revenue for Q1 2026 was $27.5 million, an increase of 25% from Q1 2025”
“2025 revenue guidance raised to $95.0 million to $96.0 million”
“Raised full-year 2025 Cell Processing platform revenue guidance to $93.0 million to $94.0 million”
The long-term thesis hinges on maintaining revenue growth and managing costs effectively to improve margins. Key forward scenarios include the potential impact of sector performance on BLFS and the risk of guidance cuts, which could negatively affect market sentiment.
In the next 1 to 3 years, BLFS's performance will depend on its ability to sustain growth amid valuation pressures and market conditions. Not investment advice.